Differentiation therapy

Current Opinion in Pharmacology

Volumn 3, Issue 4, 2003, Pages 338-343

  Spira, Alexander I ^a   Carducci, Michael A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BUPHENYL; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; IMATINIB; METHYLTRANSFERASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; RETINOID; THEOPHYLLINE; TROGLITAZONE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME INHIBITION; HEMATOPOIESIS; HUMAN; MAXIMUM TOLERATED DOSE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENIC; BUTYRATES; CELL DIFFERENTIATION; CLINICAL TRIALS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS; PHENYLBUTYRATES; RETINOIDS;

EID: 0042804927     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(03)00081-X     Document Type: Review

References (56)

1. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL) Leukemia 14 2000 491-496
2. Carducci M.A. Nelson J.B. Chan-Tack K.M. Ayyagari S.R. Sweatt W.H. Campbell P.A. Nelson W.G. Simons J.W. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate Clin. Cancer Res. 2 1996 379-387
3. Marks P.A. Richon V.M. Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J. Natl. Cancer Inst. 92 2000 1210-1216
4. Gilbert J. Baker S.D. Bowling M.K. Grochow L. Figg W.D. Zabelina Y. Donehower R.C. Carducci M.A. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies Clin. Cancer Res. 7 2001 2292-2300
5. Carducci M.A. Gilbert J. Bowling M.K. Noe D. Eisenberger M.A. Sinibaldi V. Zabelina Y. Chen T.L. Grochow L.B. Donehower R.C. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule Clin. Cancer Res. 7 2001 3047-3055
6. Tong K.P. David-Beabes G. Meeker A. Bucci J. DeWeese T. Carducci M.A. Phenylbutyrate has pleiotropic effects on gene transcription and inhibits telomerase activity in human prostate cancer Anticancer Res. 17 2003 3953-3958
7. Fisher J, Carducci M, Baker S, Phupanich S, Grossman S, Gilbert M, Piantadosi S: Dose escalation study of oral sodium phenylbutyrate in patients with refractory high grade astrocytomas (HGA): maximum tolerated dose (MTD), toxicity profile, pharmacology, and survival. Proc Am Soc Clin Oncol 2000, 645.
8. Gore S.D. Weng L.J. Figg W.D. Zhai S. Donehower R.C. Dover G. Grever M.R. Griffin C. Grochow L.B. Hawkins A. et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia Clin. Cancer Res. 8 2002 963-970.
9. Witt O. Schulze S. Kanbach K. Roth C. Pekrun A. Tumor cell differentiation by butyrate and environmental stress Cancer Lett. 171 2001 173-182
10. Davidson S.M. Morange M. Hsp25 and the p38 MAPK pathway are involved in differentiation of cardiomyocytes Dev. Biol. 218 2000 146-160
11. Goh M. Chen F. Paulsen M.T. Yeager A.M. Dyer E.S. Ljungman M. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells Neoplasia 3 2001 331-338
12. Yang G. Truong L.D. Wheeler T.M. Thompson T.C. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker Cancer Res. 59 1999 5719-5723
13. Phiel C.J. Zhang F. Huang E.Y. Guenther M.G. Lazar M.A. Klein P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J. Biol. Chem. 276 2001 36734-36741
14. Gottlicher M. Minucci S. Zhu P. Kramer O.H. Schimpf A. Giavara S. Sleeman J.P. Lo C.F. Nervi C. Pelicci P.G. Heinzel T. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells EMBO J. 20 2001 6969-6978.
15. Driever P.H. Knupfer M.M. Cinatl J. Wolff J.E. Valproic acid for the treatment of pediatric malignant glioma Klin. Padiatr. 211 1999 323-328
16. Cinatl J.Jr. Kotchetkov R. Blaheta R. Driever P.H. Vogel J.U. Cinatl J. Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha Int. J. Oncol. 20 2002 97-106
17. Matsui W.H. Gladstone D.E. Vala M.S. Barber J.P. Brodsky R.A. Smith B.D. Jones R.J. The role of growth factors in the activity of pharmacological differentiation agents Cell Growth Differ. 13 2002 275-283.
18. Cameron E.E. Bachman K.E. Myohanen S. Herman J.G. Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer Nat. Genet. 21 1999 103-107
19. Christman J.K. Mendelsohn N. Herzog D. Schneiderman N. Effect of 5-azacytidine on differentiation and DNA methylation in human promyelocytic leukemia cells (HL-60) Cancer Res. 43 1983 763-769
20. Silverman L.R. Demakos E.P. Peterson B.L. Kornblith A.B. Holland J.C. Odchimar-Reissig R. Stone R.M. Nelson D. Powell B.L. DeCastro C.M. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B J. Clin. Oncol. 20 2002 2429-2440
21. Kornblith A.B. Herndon J.E. Silverman L.R. Demakos E.P. Odchimar-Reissig R. Holland J.F. Powell B.L. DeCastro C. Ellerton J. Larson R.A. et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study J. Clin. Oncol. 20 2002 2441-2452.
22. Gore S.D. Baylin S.B. Carducci M.A. Cameron E.E. Gilbert J. Miller C.B. Herman J.G. Sequential DNA methyltransferase and histone deacetylase inhibition to re-express silenced genes: pre-clinical and early clinical modeling Proc. Am. Soc. Clin. Oncol. 42 2001 681
23. Gilbert J. Baker S.D. Donehower R.C. Herman J.G. DeMarzo A. Carducci M. Methyltransferase (MT) activity and gene expression in tumor biopsies from patients enrolled in a phase 1 study of the MT inhibitor, 5-azacytidine (5AC), and the histone deacetylase inhibitor, phenylbutyrate in refractory solid tumors Proc. Am. Soc. Clin. Oncol. 20 2001 343
24. Carducci M. Gilbert J. Herman J.G. Gore S. DeMarzo A. Baylin S.B. Clinical trials with HDAC and DNA methylation inhibitors Clin. Cancer Res. 7 2001 S3829-S3830
25. Huang M.E. Ye Y.C. Chen S.R. Zhao J.C. Gu L.J. Cai J.R. Zhao L. Xie J.X. Shen Z.X. Wang Z.Y. All-trans retinoic acid with or without low dose cytosine arabinoside in acute promyelocytic leukemia. Report of 6 cases Chin. Med. J. (Engl.) 100 1987 949-953
26. Huang M.E. Ye Y.C. Zhao L. Treatment of acute promyelocytic leukemia by retinoic acid with or without low dose cytosine arabinoside: report of 4 cases Zhonghua Nei. Ke Za Zhi 26 1987 330-332
27. Hansen L.A. Sigman C.C. Andreola F. Ross S.A. Kelloff G.J. De Luca L.M. Retinoids in chemoprevention and differentiation therapy Carcinogenesis 21 2000 1271-1279
28. Douer D. New advances in the treatment of acute promyelocytic leukemia Int. J. Hematol. 76Suppl. 2 2002 179-187
29. Gronemeyer H. Miturski R. Molecular mechanisms of retinoid action Cell Mol. Biol. Lett. 6 2001 3-52
30. Truong B.T. Lee Y.J. Lodie T.A. Park D.J. Perrotti D. Watanabe N. Koeffler H.P. Nakajima H. Tenen D.G. Kogan S.C. CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia Blood 101 2003 1141-1148.
31. Park D.J. Chumakov A.M. Vuong P.T. Chih D.Y. Gombart A.F. Miller W.H. Jr. Koeffler H.P. CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment J. Clin. Invest. 103 1999 1399-1408
32. Kini A.R. Peterson L.A. Tallman M.S. Lingen M.W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid Blood 97 2001 3919-3924
33. Ozpolat B. Lopez-Berestein G. Liposomal-all-trans-retinoic acid in treatment of acute promyelocytic leukemia Leuk Lymphoma 43 2002 933-941
34. Pili R. Kruszewski M.P. Hager B.W. Lantz J. Carducci M.A. Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis Cancer Res. 61 2001 1477-1485
35. Lin R.J. Nagy L. Inoue S. Shao W. Miller W.H. Jr. Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia Nature 391 1998 811-814
36. Samid D. Wells M. Greene M.E. Shen W. Palmer C.N. Thibault A. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity Clin. Cancer Res. 6 2000 933-941
37. Kubota T. Koshizuka K. Williamson E.A. Asou H. Said J.W. Holden S. Miyoshi I. Koeffler H.P. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo Cancer Res. 58 1998 3344-3352
38. Demetri G.D. Fletcher C.D. Mueller E. Sarraf P. Naujoks R. Campbell N. Spiegelman B.M. Singer S.Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma Proc. Natl. Acad. Sci. U.S.A. 96 1999 3951-3956
39. Guzhova I. Hultquist A. Cetinkaya C. Nilsson K. Pahlman S. Larsson L.G. Interferon-gamma cooperates with retinoic acid and phorbol ester to induce differentiation and growth inhibition of human neuroblastoma cells Int. J. Cancer 94 2001 97-108
40. Cornaglia-Ferraris P. Mariottini G.L. Ponzoni M. Gamma-interferon and retinoic acid synergize in inhibiting the growth of human neuroblastoma cells in nude mice Cancer Lett. 61 1992 215-220
41. Wuarin L. Verity M.A. Sidell N. Effects of interferon-gamma and its interaction with retinoic acid on human neuroblastoma differentiation Int. J. Cancer 48 1991 136-141
42. Miller W.H. Jr. Schipper H.M. Lee J.S. Singer J. Waxman S. Mechanisms of action of arsenic trioxide Cancer Res. 62 2002 3893-3903
43. Chen G.Q. Zhu J. Shi X.G. Ni J.H. Zhong H.J. Si G.Y. Jin X.L. Tang W. Li X.S. Xong S.M. et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins Blood 88 1996 1052-1061
44. Shao W. Fanelli M. Ferrara F.F. Riccioni R. Rosenauer A. Davison K. Lamph W.W. Waxman S. Pelicci P.G. Lo C.F. et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells J. Natl. Cancer Inst. 90 1998 124-133
45. Jing Y. Wang L. Xia L. Chen G.Q. Chen Z. Miller W.H. Waxman S. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo Blood 97 2001 264-269
46. Shen L. Chen T.X. Wang Y.P. Lin Z. Zhao H.J. Zu Y.Z. Wu G. Ying D.M. As2O3 induces apoptosis of the human B lymphoma cell line MBC-1 J. Biol. Regul. Homeost. Agents 14 2000 116-119
47. Jiang X.H. Wong B.C. Yuen S.T. Jiang S.H. Cho C.H. Lai K.C. Lin M.C. Kung H.F. Lam S.K. Chun-Yu W.B. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3 Int. J. Cancer 91 2001 173-179
48. Perkins C. Kim C.N. Fang G. Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L) Blood 95 2000 1014-1022
49. Porosnicu M. Nimmanapalli R. Nguyen D. Worthington E. Perkins C. Bhalla K.N. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells Leukemia 15 2001 772-778.
50. Benoit G. Roussel M. Pendino F. Segal-Bendirdjian E. Lanotte M. Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation Oncogene 20 2001 7161-7177
51. Guillemin M.C. Raffoux E. Vitoux D. Kogan S. Soilihi H. Lallemand-Breitenbach V. Zhu J. Janin A. Daniel M.T. Gourmel B. et al. In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia J. Exp. Med. 196 2002 1373-1380
52. Munshi N.C. Tricot G. Desikan R. Badros A. Zangari M. Toor A. Morris C. Anaissie E.Barlogie B.Clinical activity of arsenic trioxide for the treatment of multiple myeloma Leukemia 16 2002 1835-1837
53. Liu Q. Hilsenbeck S. Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase 8 or caspase 9 and synergy with APO2/TRAIL Blood 101 2003 4078-4087
54. Hayashi T. Hideshima T. Akiyama M. Richardson P. Schlossman R.L. Chauhan D. Munshi N.C. Waxman S. Anderson K.C. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment Mol. Cancer Ther. 1 2002 851-860
55. Hayashi T. Hideshima T. Anderson K.C. Novel therapies for multiple myeloma Br. J. Haematol. 120 2003 10-17
56. Hussein M.A.Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma Oncologist 7 Suppl. 1 2002 20-29